Welcome to CREANT!

CREANT is the acronym of the Center for Radiopharmaceuticals Antwerp.

What we do

We create innovative radiopharmaceutical solutions that will improve the lives of cancer patients around the globe.

Discover our research

Our mission

CREANT’s mission is to ensure that the right cancer treatment is given to the right patient at the right time. By developing radiopharmaceuticals that target specific cancer markers we aim to provide an individually tailored therapeutic intervention.

Meet the team

CREANT is driven by the enthousiasm of a large number of people.

Meet the team 

Creating innovative radiopharmaceuticals for tomorrow’s theranostics.

Our research

News

Join our mini-symposium on Cancer Radiotheranostics

Join our mini-symposium on Cancer Radiotheranostics on January 30, 2024, including the PhD defence of Karuna Adhikari.

READ MORE

Vacancy postdoctoral researcher for the development of radiopharmaceuticals

We are excited to announce an open vacancy for a full-time (100%) postdoctoral researcher in the field of radiopharmacy/radiochemistry!

READ MORE

Improved FAP-radiotheranostics for personalized cancer treatment

Improved FAP-radiotheranostics for personalized cancer treatment Cancer-associated fibroblasts (CAFs) are a group of tumor stromal cells typically associated with cancer growth and metastasis. These CAFs show high expression of the fibroblast activation protein (FAP) on the cell membrane. Due to the selective FAP expression and cancer-specific distribution, CAFs have emerged as a promising cancer diagnostic marker and an attractive therapeutic target.

READ MORE

More news
CANCER RADIOTHERANOSTICS: MINI-SYMPOSIUM (JANUARY 30, 2024)

Our partners

University of Antwerp
Molecular Imaging Center Antwerp (MICA)
Antwerp University Hospital (UZA)